Research Papers

25 of 868 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Targeting stroma and tumor, silencing galectin 1 treats orthotopic mouse hepatocellular carcinoma.
Setayesh T; Hu Y; Vaziri F; Chen X; Lai J; Wei D; Yvonne Wan YJ.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Translating bacteriophage-derived depolymerases into antibacterial therapeutics: Challenges and prospects.
Wang H; Liu Y; Bai C; Leung SSY.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Advanced nano-based strategies for mRNA tumor vaccine.
Qu Y; Xu J; Zhang T; Chen Q; Sun T; Jiang C.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Anti-atherosclerotic effects and molecular targets of ginkgolide B from <i>Ginkgo biloba</i>.
Ye W; Wang J; Little PJ; Zou J; Zheng Z; Lu J; Yin Y; Liu H; Zhang D; Liu P; Xu S; Ye W; Liu Z.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Emerging delivery systems based on aqueous two-phase systems: A review.
Zhang Y; Luo Y; Zhao J; Zheng W; Zhan J; Zheng H; Luo F.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Mitochondrial-targeted and ROS-responsive nanocarrier <i>via</i> nose-to-brain pathway for ischemic stroke treatment.
Zhang Y; Zhang H; Zhao F; Jiang Z; Cui Y; Ou M; Mei L; Wang Q.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Discovery of novel covalent selective estrogen receptor degraders against endocrine-resistant breast cancer.
Wang Y; Min J; Deng X; Feng T; Hu H; Guo X; Cheng Y; Xie B; Yang Y; Chen CC; Guo RT; Dong C; Zhou HB.
Acta Pharm Sin B (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
Orange-derived extracellular vesicles nanodrugs for efficient treatment of ovarian cancer assisted by transcytosis effe…
Long F; Pan Y; Li J; Sha S; Shi X; Guo H; Huang C; Xiao Q; Fan C; Zhang X; Fan JB; Wang Y.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors.
Fang F; Dai Y; Wang H; Ji Y; Liang X; Peng X; Li J; Zhao Y; Li C; Wang D; Li Y; Zhang D; Zhang D; Geng M; Liu H; Ai J; Zhou Y.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Development of exosome membrane materials-fused microbubbles for enhanced stability and efficient drug delivery of ultr…
Jang Y; Park J; Kim P; Park EJ; Sun H; Baek Y; Jung J; Song TK; Doh J; Kim H.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Structure-based design of novel heterocycle-substituted ATDP analogs as non-nucleoside reverse transcriptase inhibitors…
Zhao LM; Pannecouque C; Clercq E; Wang S; Chen FE.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Discovery and druggability evaluation of pyrrolamide-type GyrB/ParE inhibitor against drug-resistant bacterial infectio…
Zhao X; Feng J; Zhang J; Han Z; Hu Y; Shao HH; Li T; Xia J; Lei K; Wang W; Lai F; Lin Y; Liu B; Zhang K; Zhang C; Yang Q; Luo X; Zhang H; Li C; Zhang W; Wu S.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Targeting autophagy and beyond: Deconvoluting the complexity of Beclin-1 from biological function to cancer therapy.
Ye J; Zhang J; Zhu Y; Wang L; Jiang X; Liu B; He G.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Immunogenicity of mucosal COVID-19 vaccine candidates based on the highly attenuated vesicular stomatitis virus vector …
Ke Y; Zhang E; Guo J; Zhang X; Wang L; Chen D; Fang X; Zhu J; Li F; Sun T; Zhang B.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Nanoparticles (NPs)-mediated Siglec15 silencing and macrophage repolarization for enhanced cancer immunotherapy.
Liu X; Zhang Q; Liang Y; Xiong S; Cai Y; Cao J; Xu Y; Xu X; Wu Y; Lu Q; Xu X; Luo B.
Acta Pharm Sin B (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
A unique binding pocket induced by a noncanonical SAH mimic to develop potent and selective PRMT inhibitors.
Deng Y; Song X; Iyamu ID; Dong A; Min J; Huang R.
Acta Pharm Sin B (Unknown)
Published: 2023
4/6 Transparent
Data Funding Declared
ACAT1 deficiency in myeloid cells promotes glioblastoma progression by enhancing the accumulation of myeloid-derived su…
Wang M; Wang W; You S; Hou Z; Ji M; Xue N; Du T; Chen X; Jin J.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Remodeling of the liver fibrosis microenvironment based on nilotinib-loaded multicatalytic nanozymes with boosted antif…
Jing H; Ren Y; Zhou Y; Xu M; Krizkova S; Heger Z; Lu Q; Wang S; Liang X; Adam V; Li N.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Discovery of a highly potent and orally available importin-<i>β</i>1 inhibitor that overcomes enzalutamide-resistance i…
Huang JL; Yan XL; Huang D; Gan L; Gao H; Fan RZ; Li S; Yuan FY; Zhu X; Tang GH; Chen HW; Wang J; Yin S.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Emerging drug design strategies in anti-influenza drug discovery.
Liu C; Hu L; Dong G; Zhang Y; Ferreira da Silva-Júnior E; Liu X; Menéndez-Arias L; Zhan P.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Targeting the blood-brain barrier to delay aging-accompanied neurological diseases by modulating gut microbiota, circad…
Wang Y; Du W; Hu X; Yu X; Guo C; Jin X; Wang W.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
An injectable signal-amplifying device elicits a specific immune response against malignant glioblastoma.
Qiu Q; Chen S; He H; Chen J; Ding X; Wang D; Yang J; Guo P; Li Y; Kim J; Sheng J; Gao C; Yin B; Zheng S; Wang J.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Activation of PXR causes drug interactions with Paxlovid in transgenic mice.
Lei S; Guo A; Lu J; Qi Q; Devanathan AS; Zhu J; Ma X.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Targeting Kindlin-2 in adipocytes increases bone mass through inhibiting FAS/PPAR<i>γ</i>/FABP4 signaling in mice.
Tang W; Ding Z; Gao H; Yan Q; Liu J; Han Y; Hou X; Liu Z; Chen L; Yang D; Ma G; Cao H.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Function, mechanism and drug discovery of ubiquitin and ubiquitin-like modification with multiomics profiling for cance…
Jiang Y; Ni S; Xiao B; Jia L.
Acta Pharm Sin B (Unknown)
Published: 2023
3/6 Transparent
Funding Declared